$10.36
4.34% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US03969K1088
Symbol
ARQT
Sector
Industry

Arcutis Biotherapeutics Inc Target price 2024 - Analyst rating & recommendation

Arcutis Biotherapeutics Inc Classifications & Recommendation:

Buy
86%
Hold
14%

Arcutis Biotherapeutics Inc Price Target

Target Price $18.57
Price $10.36
Potential
Number of Estimates 7
7 Analysts have issued a price target Arcutis Biotherapeutics Inc 2025 . The average Arcutis Biotherapeutics Inc target price is $18.57. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 6 Analysts recommend Arcutis Biotherapeutics Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Arcutis Biotherapeutics Inc stock has an average upside potential 2025 of . Most analysts recommend the Arcutis Biotherapeutics Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 59.61 166.56
1,515.45% 179.42%
EBITDA Margin -401.31% -101.21%
95.07% 74.78%
Net Margin -738.63% -108.57%
95.87% 85.30%

7 Analysts have issued a sales forecast Arcutis Biotherapeutics Inc 2024 . The average Arcutis Biotherapeutics Inc sales estimate is

$167m
Unlock
. This is
26.13% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$182m 38.17%
Unlock
, the lowest is
$159m 20.40%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $59.6m 1,515.45%
2024
$167m 179.42%
Unlock
2025
$247m 48.50%
Unlock
2026
$393m 59.00%
Unlock
2027
$602m 53.11%
Unlock
2028
$762m 26.59%
Unlock

2 Analysts have issued an Arcutis Biotherapeutics Inc EBITDA forecast 2024. The average Arcutis Biotherapeutics Inc EBITDA estimate is

$-169m
Unlock
. This is
5.45% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-162m 9.09%
Unlock
, the lowest is
$-175m 1.80%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-239m 20.36%
2024
$-169m 29.53%
Unlock
2025
$-145m 14.13%
Unlock
2026
$-56.4m 61.06%
Unlock

EBITDA Margin

2023 -401.31% 95.07%
2024
-101.21% 74.78%
Unlock
2025
-58.52% 42.18%
Unlock
2026
-14.33% 75.51%
Unlock

4 Arcutis Biotherapeutics Inc Analysts have issued a net profit forecast 2024. The average Arcutis Biotherapeutics Inc net profit estimate is

$-181m
Unlock
. This is
28.78% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-171m 32.57%
Unlock
, the lowest is
$-203m 20.18%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-440m 33.22%
2024
$-181m 58.93%
Unlock
2025
$-127m 29.58%
Unlock
2026
$-2.7m 97.86%
Unlock
2027
$208m 7,744.12%
Unlock
2028
$359m 72.83%
Unlock

Net Margin

2023 -738.63% 95.87%
2024
-108.57% 85.30%
Unlock
2025
-51.49% 52.57%
Unlock
2026
-0.69% 98.66%
Unlock
2027
34.53% 5,104.35%
Unlock
2028
47.14% 36.52%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.78 -1.55
33.22% 58.99%
P/E negative
EV/Sales 6.34

4 Analysts have issued a Arcutis Biotherapeutics Inc forecast for earnings per share. The average Arcutis Biotherapeutics Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-1.55
Unlock
. This is
28.90% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-1.47 32.57%
Unlock
, the lowest is
$-1.74 20.18%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.78 33.22%
2024
$-1.55 58.99%
Unlock
2025
$-1.09 29.68%
Unlock
2026
$-0.02 98.17%
Unlock
2027
$1.79 9,050.00%
Unlock
2028
$3.09 72.63%
Unlock

P/E ratio

Current -4.74 1,056.10%
2024
-6.67 40.72%
Unlock
2025
-9.48 42.13%
Unlock
2026
-444.01 4,583.65%
Unlock
2027
5.80 101.31%
Unlock
2028
3.36 42.07%
Unlock

Based on analysts' sales estimates for 2024, the Arcutis Biotherapeutics Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.99 93.95%
2024
6.34 20.69%
Unlock
2025
4.27 32.66%
Unlock
2026
2.68 37.11%
Unlock
2027
1.75 34.69%
Unlock
2028
1.38 21.01%
Unlock

P/S ratio

Current 9.17 93.87%
2024
7.27 20.71%
Unlock
2025
4.90 32.66%
Unlock
2026
3.08 37.11%
Unlock
2027
2.01 34.69%
Unlock
2028
1.59 21.00%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today